Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Anthoney

Showing results (31-40 of 34) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 34 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 10, 2018
Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 'CREATE'P Schöffski, A Wozniak, S Stacchiotti, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 8, 2017
Activity and safety of crizotinib in patients with alveolar soft part sarcoma with rearrangement of TFE3: European Organization for Research and Treatment of Cancer (EORTC) phase II trial 90101 'CREATE'P Schöffski, A Wozniak, B Kasper, et al.
British Journal of Cancer|March 11, 2018
Intratumoural expression of deoxycytidylate deaminase or ribonuceotide reductase subunit M1 expression are not related to survival in patients with resected pancreatic cancer given adjuvant chemotherapyN O Elander, K Aughton, P Ghaneh, et al.
British Journal of Cancer|May 1, 2020
Scheduling nab-paclitaxel combined with gemcitabine as first-line treatment for metastatic pancreatic adenocarcinomaP G Corrie, W Qian, B Basu, et al.
Pageof 4

Showing results (31-40 of 34) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 34 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 10, 2018
Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 'CREATE'P Schöffski, A Wozniak, S Stacchiotti, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 8, 2017
Activity and safety of crizotinib in patients with alveolar soft part sarcoma with rearrangement of TFE3: European Organization for Research and Treatment of Cancer (EORTC) phase II trial 90101 'CREATE'P Schöffski, A Wozniak, B Kasper, et al.
British Journal of Cancer|March 11, 2018
Intratumoural expression of deoxycytidylate deaminase or ribonuceotide reductase subunit M1 expression are not related to survival in patients with resected pancreatic cancer given adjuvant chemotherapyN O Elander, K Aughton, P Ghaneh, et al.
British Journal of Cancer|May 1, 2020
Scheduling nab-paclitaxel combined with gemcitabine as first-line treatment for metastatic pancreatic adenocarcinomaP G Corrie, W Qian, B Basu, et al.
Pageof 4